Estrogen receptor β ligands: Recent advances and biomedical applications

Filippo Minutolo, Marco Macchia, Benita S Katzenellenbogen, John A. Katzenellenbogen

Research output: Contribution to journalArticle

Abstract

Recent work elucidating the role that the estrogen receptor β (ERβ), a member of the nuclear receptor superfamily, plays in regulating various physiological functions has highlighted the potential of this receptor subtype as a therapeutic target for several pathologies. In fact, molecules that are able to selectively activate ERβ hold promise for the treatment of certain cancers, as well as endometriosis, inflammatory diseases including rheumatoid arthritis, and cardiovascular and CNS conditions. Nevertheless, ERβ remains a challenging target because its ligand-binding cavity is very similar to that present in ERα, and this makes it difficult to develop ligands having sufficient levels of ERβ selectivity for therapeutic use. Nevertheless, considerable advances have recently been made in developing both nonsteroidal and steroidal ERβ-selective agonists. These molecules constitute not only important tools to probe the biological effects of the selective stimulation of ERβ, but some of them appear to be agents with considerable therapeutic potential. This study provides a detailed review of selective ERβ ligands that have been developed recently. After a brief introduction to the structure and nature of the two ERs and the biology of ERβ and its isoforms, the ligands are classified on the basis of their structures and activities. Common pharmacophore elements are highlighted throughout the description of the various chemical classes analyzed, and these elements are presented in a concluding summary overview along with a discussion of potential therapeutic applications of these agents in biomedicine.

Original languageEnglish (US)
Pages (from-to)364-442
Number of pages79
JournalMedicinal Research Reviews
Volume31
Issue number3
DOIs
StatePublished - May 1 2011

Fingerprint

Estrogen Receptors
Ligands
Non-Steroidal Estrogens
Therapeutic Uses
Endometriosis
Cytoplasmic and Nuclear Receptors
Rheumatoid Arthritis
Protein Isoforms
Estrogens
Therapeutics
Pathology
Neoplasms

Keywords

  • Agonist
  • Antagonist
  • Binding
  • Estrogen receptor β
  • Estrogens
  • Ligand
  • Pharmacophore

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Estrogen receptor β ligands : Recent advances and biomedical applications. / Minutolo, Filippo; Macchia, Marco; Katzenellenbogen, Benita S; Katzenellenbogen, John A.

In: Medicinal Research Reviews, Vol. 31, No. 3, 01.05.2011, p. 364-442.

Research output: Contribution to journalArticle

Minutolo, Filippo ; Macchia, Marco ; Katzenellenbogen, Benita S ; Katzenellenbogen, John A. / Estrogen receptor β ligands : Recent advances and biomedical applications. In: Medicinal Research Reviews. 2011 ; Vol. 31, No. 3. pp. 364-442.
@article{691c10b6a6574591a11711ca597cd7fd,
title = "Estrogen receptor β ligands: Recent advances and biomedical applications",
abstract = "Recent work elucidating the role that the estrogen receptor β (ERβ), a member of the nuclear receptor superfamily, plays in regulating various physiological functions has highlighted the potential of this receptor subtype as a therapeutic target for several pathologies. In fact, molecules that are able to selectively activate ERβ hold promise for the treatment of certain cancers, as well as endometriosis, inflammatory diseases including rheumatoid arthritis, and cardiovascular and CNS conditions. Nevertheless, ERβ remains a challenging target because its ligand-binding cavity is very similar to that present in ERα, and this makes it difficult to develop ligands having sufficient levels of ERβ selectivity for therapeutic use. Nevertheless, considerable advances have recently been made in developing both nonsteroidal and steroidal ERβ-selective agonists. These molecules constitute not only important tools to probe the biological effects of the selective stimulation of ERβ, but some of them appear to be agents with considerable therapeutic potential. This study provides a detailed review of selective ERβ ligands that have been developed recently. After a brief introduction to the structure and nature of the two ERs and the biology of ERβ and its isoforms, the ligands are classified on the basis of their structures and activities. Common pharmacophore elements are highlighted throughout the description of the various chemical classes analyzed, and these elements are presented in a concluding summary overview along with a discussion of potential therapeutic applications of these agents in biomedicine.",
keywords = "Agonist, Antagonist, Binding, Estrogen receptor β, Estrogens, Ligand, Pharmacophore",
author = "Filippo Minutolo and Marco Macchia and Katzenellenbogen, {Benita S} and Katzenellenbogen, {John A.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1002/med.20186",
language = "English (US)",
volume = "31",
pages = "364--442",
journal = "Medicinal Research Reviews",
issn = "0198-6325",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Estrogen receptor β ligands

T2 - Recent advances and biomedical applications

AU - Minutolo, Filippo

AU - Macchia, Marco

AU - Katzenellenbogen, Benita S

AU - Katzenellenbogen, John A.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Recent work elucidating the role that the estrogen receptor β (ERβ), a member of the nuclear receptor superfamily, plays in regulating various physiological functions has highlighted the potential of this receptor subtype as a therapeutic target for several pathologies. In fact, molecules that are able to selectively activate ERβ hold promise for the treatment of certain cancers, as well as endometriosis, inflammatory diseases including rheumatoid arthritis, and cardiovascular and CNS conditions. Nevertheless, ERβ remains a challenging target because its ligand-binding cavity is very similar to that present in ERα, and this makes it difficult to develop ligands having sufficient levels of ERβ selectivity for therapeutic use. Nevertheless, considerable advances have recently been made in developing both nonsteroidal and steroidal ERβ-selective agonists. These molecules constitute not only important tools to probe the biological effects of the selective stimulation of ERβ, but some of them appear to be agents with considerable therapeutic potential. This study provides a detailed review of selective ERβ ligands that have been developed recently. After a brief introduction to the structure and nature of the two ERs and the biology of ERβ and its isoforms, the ligands are classified on the basis of their structures and activities. Common pharmacophore elements are highlighted throughout the description of the various chemical classes analyzed, and these elements are presented in a concluding summary overview along with a discussion of potential therapeutic applications of these agents in biomedicine.

AB - Recent work elucidating the role that the estrogen receptor β (ERβ), a member of the nuclear receptor superfamily, plays in regulating various physiological functions has highlighted the potential of this receptor subtype as a therapeutic target for several pathologies. In fact, molecules that are able to selectively activate ERβ hold promise for the treatment of certain cancers, as well as endometriosis, inflammatory diseases including rheumatoid arthritis, and cardiovascular and CNS conditions. Nevertheless, ERβ remains a challenging target because its ligand-binding cavity is very similar to that present in ERα, and this makes it difficult to develop ligands having sufficient levels of ERβ selectivity for therapeutic use. Nevertheless, considerable advances have recently been made in developing both nonsteroidal and steroidal ERβ-selective agonists. These molecules constitute not only important tools to probe the biological effects of the selective stimulation of ERβ, but some of them appear to be agents with considerable therapeutic potential. This study provides a detailed review of selective ERβ ligands that have been developed recently. After a brief introduction to the structure and nature of the two ERs and the biology of ERβ and its isoforms, the ligands are classified on the basis of their structures and activities. Common pharmacophore elements are highlighted throughout the description of the various chemical classes analyzed, and these elements are presented in a concluding summary overview along with a discussion of potential therapeutic applications of these agents in biomedicine.

KW - Agonist

KW - Antagonist

KW - Binding

KW - Estrogen receptor β

KW - Estrogens

KW - Ligand

KW - Pharmacophore

UR - http://www.scopus.com/inward/record.url?scp=79953321479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953321479&partnerID=8YFLogxK

U2 - 10.1002/med.20186

DO - 10.1002/med.20186

M3 - Article

C2 - 19967775

AN - SCOPUS:79953321479

VL - 31

SP - 364

EP - 442

JO - Medicinal Research Reviews

JF - Medicinal Research Reviews

SN - 0198-6325

IS - 3

ER -